M. Scot Roberts - 30 Jan 2023 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Chief Scientific Officer
Signature
/s/ Richard Eisenstadt, as Attorney-in-Fact
Issuer symbol
ALT
Transactions as of
30 Jan 2023
Transactions value $
$0
Form type
4
Filing time
01 Feb 2023, 16:31:51 UTC
Previous filing
03 Aug 2022
Next filing
02 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Award $0 +105K $0.00 105K 30 Jan 2023 Common Stock, par value $0.0001 105K $12.88 Direct F1
transaction ALT Restricted Stock Units Award $0 +37.1K $0.00 37.1K 30 Jan 2023 Common Stock, par value $0.0001 37.1K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent of the shares underlying the option become vested and exercisable on January 30, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 30, 2024, subject to the reporting person's continued service through the applicable vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F3 The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.